VistaGen Therapeutics WKN: A3EHA1 ISIN: US92840H4002 Kürzel: VTGN Forum: Aktien Thema: Hauptdiskussion

https://investorplace.com/2024/02/3-penny-stocks-to-buy-for-the-next-bull-run-february-2024/

Vistagen begibt sich auf seinen Weg....

Vista beginnt wieder auszubrechen... oberhalb von 4,20 Dollar seh ich Kursziel 7 Dollar

https://www.schaeffersresearch.com/content/news/2023/11/14/vistagen-therapeutics-stock-jumps-on-fresh-coverage

Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results https://www.businesswire.com/news/home/20231109410625/en/Vistagen-Provides-Corporate-Update-and-Reports-Fiscal-2024-Second-Quarter-Financial-Results

👀🌻

Nachbörslich 15% hoch.... SEC Einreichung....Citadel Advisors LLC....erreicht 5,6% Anteile.

Mittelfristig betrachtet muß Vista jetzt 3,80 Dollar überwinden, und halten....dann stünde hier jetzt einiges an...

https://beststocks.com/point72-asset-management-lp-acquires-56-stake/

Zwei Dumme, ein Gedanke....

https://www.businesswire.com/news/home/20231002934206/en/Vistagen-Announces-Pricing-of-100-Million-Underwritten-Offering

Vistagen Announces Pricing of $100 Million Underwritten Offering https://www.businesswire.com/news/home/20231002934206/en/Vistagen-Announces-Pricing-of-100-Million-Underwritten-Offering

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder

Vistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagen’s Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan https://www.businesswire.com/news/home/20230905339975/en/Vistagen-and-Fuji-Enter-Exclusive-Negotiation-Agreement-for-a-Potential-License-to-Develop-and-Commercialize-Vistagen%E2%80%99s-Investigational-Menopausal-Hot-Flash-Therapy-PH80-Nasal-Spray-in-Japan Vistagen to receive $1.5 million and Fuji to obtain time-limited exclusive negotiation period for the Japanese market Recently reported exploratory Phase 2A study in women diagnosed with menopausal hot flashes demonstrated PH80’s statistically significant reduction in the number of hot flashes and the severity, disruption in function, and sweating related to hot flashes as compared with placebo

Vistagen ist sehr klein...aber sie sind dabei ein großes Problem der Menschen zu lösen.... vielleicht....Fast Track Designation....wir werden sehen....

Ich sehe hier 25 Leute...ich denke, wir werden bald mehr werden.